Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy

Simple item page
dc.contributor.authorMurray, N. P.
dc.contributor.authorReyes, E.
dc.contributor.authorTapia, P.
dc.contributor.authorBadinez, L.
dc.contributor.authorOrellana, N.
dc.contributor.authorFuentealba, C.
dc.contributor.authorOlivares, R.
dc.contributor.authorPorcell, J.
dc.contributor.authorDuenas, R.
dc.date.accessioned2025-01-20T23:56:41Z
dc.date.available2025-01-20T23:56:41Z
dc.date.issued2012
dc.description.abstractThe presence of cells positive for cytokeratins or prostate-specific antigen (PSA) in bone marrow aspirates (BMAs) has been used to indicate the presence of micrometastasis. The aim of this prospective study of prostate cancer patients was to determine the presence of prostate cells in blood and BMAs and to compare them with bone marrow biopsy touch prep samples. The results indicated that there was a satisfactory concordance between circulating prostate cells (CPCs) in blood and disseminated tumor cells (DTCs) in BMAs for all Gleason scores (kappa>0.50). However, neither were concordant with the presence of prostate cells in bone marrow biopsies except for high-grade tumors, Gleason 8 and 9. Phenotypic characteristics of CPCs and DTCs were identical (kappa>0.9) but were different than cells detected in bone marrow biopsies (kappa<0.2). The expression of matrix metalloproteinase-2 (MMP-2) in bone marrow biopsies was positively associated with the Gleason score (trend Chi-squared <0.05) and may explain the differences between the presence of DTCs and the presence of prostate cells in bone marrow biopsies. If the presence of DTCs was used to indicate micrometastatic disease, 20% of patients would be misclassified compared to micrometastasis defined as patients with a positive biopsy. This may have clinical implications for patients with low-grade tumors.
dc.fuente.origenWOS
dc.identifier.doi10.3892/ijmm.2012.1071
dc.identifier.eissn1791-244X
dc.identifier.issn1107-3756
dc.identifier.urihttps://doi.org/10.3892/ijmm.2012.1071
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/95170
dc.identifier.wosidWOS:000309298000024
dc.issue.numero4
dc.language.isoen
dc.pagina.final904
dc.pagina.inicio896
dc.revistaInternational journal of molecular medicine
dc.rightsacceso restringido
dc.subjectcirculating prostate cells
dc.subjectdisseminated tumor cells
dc.subjectmicrometastasis
dc.subjectbone marrow
dc.subjectprostate cancer
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleRedefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy
dc.typeartículo
dc.volumen30
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas